A new drug has been approved for intravenous therapy of hypertension...Cleviprex (clevidipine butyrate injectable emulsion).
From The Medicines Company's press release.
The Medicines Company (NASDAQ: MDCO) announced today that the U.S.Food and Drug Administration (FDA) has approved the intravenous (IV)therapy Cleviprex(TM) (clevidipine butyrate) injectable emulsion forthe reduction of blood pressure when oral therapy is not feasible or not desirable. Cleviprex, a
novel IV antihypertensive, represents an advancement over currently available
therapies, providing rapid and precise control of blood pressure in the critical
care setting. Backed by comprehensive data in the emergency department, operating room and intensive care unit, Cleviprex offers physicians an important
new therapeutic option for the management of blood pressure.
It appears more suited for the ED setting where a prolonged infusion might be required in the setting of malignant hypertension. Not quite sure this drug would have any significant advantage over NTG of Nitroprusside in the operating room. Any experiences? Please share.
0 comments:
Post a Comment